23 research outputs found
The genetic landscape of immune-competent and HIV lymphoma
This journal supplement is Proceedings of the 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)Open Access JournalBurkitt lymphoma (BL) and diffuse large B cell lymphoma (DLBCL) are aggressive forms of lymphoma in adults and demonstrate overlapping morphology, immunophenotype and clinical behavior. The risk of developing these tumors increases ten to hundred-fold in the setting of HIV infection. The genetic causes and the role of specific mutations, especially in the setting of HIV, are largely unknown.
The decoding of the human genome and the advent of high-throughput sequencing have provided rich opportunities for the comprehensive identification of the genetic causes of cancer. In order to comprehensively identify genes that are recurrently mutated in immune-competent DLBCL and BL, we obtained a total of 92 cases of DLBCLs and 40 cases of BL. These cases were compared to a set of 5 DLBCLs and BL tumors derived from patients with HIV. The DLBCL cases were divided into a discovery set (N=34) and …link_to_OA_fulltextThe 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICAMAOI), Bethesda, MD., 7-8 November 2011. In Infectious Agents and Cancer, 2011, v. 7 suppl. 1, article no. O
Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2
Enteropathy-associated T cell lymphoma (EATL) is a lethal, and the most common, neoplastic complication of celiac disease. Here, we defined the genetic landscape of EATL through whole-exome sequencing of 69 EATL tumors. SETD2 was the most frequently silenced gene in EATL (32% of cases). The JAK-STAT pathway was the most frequently mutated pathway, with frequent mutations in STAT5B as well as JAK1 , JAK3 , STAT3 , and SOCS1 . We also identified mutations in KRAS , TP53 , and TERT . Type I EATL and type II EATL (monomorphic epitheliotropic intestinal T cell lymphoma) had highly overlapping genetic alterations indicating shared mechanisms underlying their pathogenesis. We modeled the effects of SETD2 loss in vivo by developing a T cell–specific knockout mouse. These mice manifested an expansion of γδ T cells, indicating novel roles for SETD2 in T cell development and lymphomagenesis. Our data render the most comprehensive genetic portrait yet of this uncommon but lethal disease and may inform future classification schemes
The genetic landscape of mutations in Burkitt lymphoma
Burkitt lymphoma is characterized by deregulation of MYC, but the contribution of other genetic mutations to the disease is largely unknown. Here, we describe the first completely sequenced genome from a Burkitt lymphoma tumor and germline DNA from the same affected individual. We further sequenced the exomes of 59 Burkitt lymphoma tumors and compared them to sequenced exomes from 94 diffuse large B-cell lymphoma (DLBCL) tumors. We identified 70 genes that were recurrently mutated in Burkitt lymphomas, including ID3, GNA13, RET, PIK3R1 and the SWI/SNF genes ARID1A and SMARCA4. Our data implicate a number of genes in cancer for the first time, including CCT6B, SALL3, FTCD and PC. ID3 mutations occurred in 34% of Burkitt lymphomas and not in DLBCLs. We show experimentally that ID3 mutations promote cell cycle progression and proliferation. Our work thus elucidates commonly occurring gene-coding mutations in Burkitt lymphoma and implicates ID3 as a new tumor suppressor gene
Genetic heterogeneity of diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form
of lymphoma in adults. The disease exhibits a striking heterogeneity
in gene expression profiles and clinical outcomes, but its
genetic causes remain to be fully defined. Through whole genome
and exome sequencing, we characterized the genetic diversity of
DLBCL. In all, we sequenced 73 DLBCL primary tumors (34 with
matched normal DNA). Separately, we sequenced the exomes of
21 DLBCL cell lines. We identified 322 DLBCL cancer genes that
were recurrently mutated in primary DLBCLs. We identified recurrent
mutations implicating a number of known and not previously
identified genes and pathways in DLBCL including those related to
chromatin modification (ARID1A and MEF2B), NF-κB (CARD11 and
TNFAIP3), PI3 kinase (PIK3CD, PIK3R1, and MTOR), B-cell lineage
(IRF8, POU2F2, and GNA13), and WNT signaling (WIF1). We also
experimentally validated a mutation in PIK3CD, a gene not previously
implicated in lymphomas. The patterns of mutation demonstrated
a classic long tail distribution with substantial variation
of mutated genes from patient to patient and also between published
studies. Thus, our study reveals the tremendous genetic
heterogeneity that underlies lymphomas and highlights the need
for personalized medicine approaches to treating these patients
Molecular Characterization of Circulating Plasma Cells in Patients with Active Systemic Lupus Erythematosus
<div><p>Systemic lupus erythematosus (SLE) is a generalized autoimmune disease characterized by abnormal B cell activation and the occurrence of increased frequencies of circulating plasma cells (PC). The molecular characteristics and nature of circulating PC and B cells in SLE have not been completely characterized. Microarray analysis of gene expression was used to characterize circulating PC in subjects with active SLE. Flow cytometry was used to sort PC and comparator B cell populations from active SLE blood, normal blood and normal tonsil. The gene expression profiles of the sorted B cell populations were then compared.</p> <p>SLE PC exhibited a similar gene expression signature as tonsil PC. The differences in gene expression between SLE PC and normal tonsil PC and tonsil plasmablasts (PB) suggest a mature Ig secreting cell phenotype in the former population. Despite this, SLE PC differed in expression of about half the genes from previously published gene expression profiles of normal bone marrow PC, indicating that these cells had not achieved a fully mature status. Abnormal expression of several genes, including <em>CXCR4</em> and <em>S1P<sub>1</sub></em>, suggests a mechanism for the persistence of SLE PC in the circulation. All SLE B cell populations revealed an interferon (IFN) gene signature previously only reported in unseparated SLE peripheral blood mononuclear cells. These data indicate that SLE PC are a unique population of Ig secreting cells with a gene expression profile indicative of a mature, but not fully differentiated phenotype.</p> </div
Differentially expressed genes in SLE PC compared to tonsil Ig secreting cells.
<p>77 differentially expressed genes in SLE PC compared to tonsil PC and 72 differentially expressed genes in SLE PC compared to tonsil PB, both identified by SAM. The bolded genes represent genes upregulated in SLE PC compared to tonsil Ig secreting cells. The genes in italics represent downregulated genes compared with tonsil Ig secreting cells. The asterisk denotes genes common to both comparisons. Gene function adapted from NCBI Gene and HPRD (Human Protein Reference Database).</p
Gene expression profiling of sorted tonsil B cell populations.
<p>The heatmap shown represents the differential gene expression identified using- SAM in tonsil PC (TPC), tonsil naïve, pre-GC/germinal center founder (GCF), dark zone/germinal center (GC) and memory B cells. A total of 1858 genes are shown. 1690 are upregulated and 168 are downregulated. The majority of the gene signature is shared with tonsil PB (TPB).</p
Gene expression profiling of circulating SLE B cells populations demonstrating the differential gene expression in SLE PC compared with SLE naïve and memory B cells.
<p><b>A</b>. 780 genes are differentially expressed in SLE PC compared to SLE naive and memory B cells identified using SAM. 571 genes shown in the heatmap are upregulated and 209 genes are downregulated in SLE PC compared to SLE naïve and memory B cells. <b>B</b>. The genes differentially expressed in SLE PC were then compared gene by gene for corresponding expression in sorted tonsillar B cell populations.</p
Proposed plasma cell trafficking in SLE based on gene expression profiling.
<p>Normal B cell traffic into germinal center reactions appears unchanged in SLE from normal. Plasma cells in SLE differ from tonsil plasma cells in expression of cell surface markers that may affect plasma cell homing to bone marrow. Plasma cells continue to mature in the blood and have a gene program upregulated similar to bone marrow plasma cells with long-lived potential. Downregulated gene program include continued and more pronounced decrease in expression of CXCR4, MHC class II and cell surface markers. Endogenous factors such as IFN<i>α</i> in SLE may contribute to these changes.</p